FDA Acceptance of Foreign Clinical Studies

FDA Acceptance of Foreign Clinical Studies (21 CFR 312.120)

FDA Acceptance of Foreign Clinical Studies (21 CFR 312.120) allows sponsors to use foreign clinical trial data for U.S. marketing applications, even if the study was not conducted under an IND. Under FDA Acceptance of Foreign Clinical Studies (21 CFR 312.120), the FDA accepts data when trials follow Good Clinical Practice (GCP), ensure patient protection, and produce reliable, verifiable results.

Key Conditions for FDA Acceptance of Foreign Clinical Studies (21 CFR 312.120)

Conducted in compliance with GCP (ICH E6 aligned)
Data can be validated by FDA inspection if required
Study is adequate and well-controlled
Results are applicable to the U.S. population and medical practice

Documentation Expectations

Investigator qualifications and training
Details of research facilities
Full Clinical Study Report (ICH E3 format)
Ethics Committee (IEC) approval and oversight
Proper informed consent process
Evidence of sponsor monitoring and auditing

FDA may grant waivers where local laws restrict documentation. Sponsors must retain records for at least 2 years after regulatory decisions.

In summary, FDA Acceptance of Foreign Clinical Studies (21 CFR 312.120) enables global data to support U.S. approvals, provided ethical, scientific, and regulatory standards are fully met.